Author: kaiser

Executive Director, Nimbus Therapeutics. US “Discovery of NTX-801, a potent Cbl-b inhibitor with antitumor activity in syngeneic models”

University of KwaZulu-Natal “In Vitro and In Vivo Development of β-Lactam-Metallo-β-Lactamase Inhibitors: Targeting Carbapenem-Resistant Enterobacterales”

University of Minnesota “3′-Deoxy-3′,4′-didehydro-nucleosides and ProTides as Potent Antiviral Agents”

University of Strasbourg “Reaction-driven generation of bioactive compounds from ultra-large chemical spaces”

Ottawa Institute of Systems Biology, University of Ottawa “Synergizing Computational Chemistry and AI for Early-Stage Drug Discovery”

Emory University, Atlanta, GA, USA “Connecting Biology to Chemistry through High Throughput Screening”

Senior Principal Research Scientist, Abbvie, USA “Discovery and Development of CFTR Modulators for the Treatment of Cystic Fibrosis”

University of Heidelberg “Microfluidic “organ-on-a-chip” tissue culture model systems for drug testing and toxicity studies”

Medicines for Malaria Venture “Replenishing the malaria drug discovery pipeline: Advances in Hit Generation for Antimalarial Drug Discovery”

Wellcome Centre for Anti-Infectives Research, School of Life Sciences, University of Dundee “The direct approach: the role of chemical proteomics in drug target deconvolution”